Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System
Not Applicable
Completed
- Conditions
- Nebulizers and Vaporizers
- Interventions
- Other: Seretide Evohaler forteDevice: PreciseInhale
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Inhalation Sciences Sweden AB
- Target Recruit Count
- 12
- Registration Number
- NCT04946630
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath